BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-12
557 industry Phase 2/3 trial readout(s) and 4 FDA decision event(s). Active trials only; estimated dates often slip.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-12-12 | PDUFA date (company-disclosed) | pending | ANAPTYSBIO, INC ANAB | imsidolimab | PDUFA Dec. 12, 2026 - ANAPTYSBIO, INC (imsidolimab) |
| 2026-12-12 | PDUFA date (company-disclosed) | pending | Vanda Pharmaceuticals Inc. VNDA | imsidolimab | PDUFA December 12, 2026 - Vanda Pharmaceuticals Inc. (imsidolimab) |
| 2026-12-22 | PDUFA date (company-disclosed) | pending | Mineralys Therapeutics, Inc. MLYS | lorundrostat | PDUFA December 22, 2026 - Mineralys Therapeutics, Inc. (lorundrostat) |
| 2026-12-27 | PDUFA date (company-disclosed) | pending | Praxis Precision Medicines, Inc. PRAX | ulixacaltamide | PDUFA December 27, 2026 - Praxis Precision Medicines, Inc. (ulixacaltamide) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Italfarmaco | NCT01761968 Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | Chronic Myeloproliferative Neoplasms | active not recruiting | 90 |
| 2026-12 est. | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT02227251 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | active not recruiting | 244 |
| 2026-12 est. | P2 | SynerGene Therapeutics, Inc. | NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | active not recruiting | 28 |
| 2026-12 est. | P3 | Supernus Pharmaceuticals, Inc. SUPN | NCT02736656 Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | Attention-Deficit/Hyperactivity Disorder | active not recruiting | 1400 |
| 2026-12 est. | P1/P2 | Cancer Vaccines Limited | NCT03096093 Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer | Cancer; Neoplasms | active not recruiting | 34 |
| 2026-12 est. | P2 | CivaTech Oncology | NCT03290534 Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet® | Lung Cancer; Lung Cancer Stage I; Lung Cancer Stage II | recruiting | 40 |
| 2026-12 est. | P2 | Corcept Therapeutics CORT | NCT03604198 Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | Cushing Syndrome | active not recruiting | 125 |
| 2026-12 est. | P3 | United Therapeutics UTHR | NCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseas | enrolling by invitation | 1000 |
| 2026-12 est. | P3 | Tasly Pharmaceuticals, Inc. | NCT03789552 Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina | Chronic Stable Angina Pectoris | recruiting | 765 |
| 2026-12 est. | P2 | Theralase® Technologies Inc. TLTFF | NCT03945162 Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients | Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG | recruiting | 90 |
| 2026-12 est. | P1/P2 | Iperboreal Pharma Srl | NCT03994874 Peritoneal Ultrafiltration in Cardio Renal Syndrome. | Congestive Heart Failure | recruiting | 84 |
| 2026-12 est. | P2 | BioRestorative Therapies BRTX | NCT04042844 A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD) | Lumbar Disc Disease | recruiting | 99 |
| 2026-12 est. | P1/P2 | Phoenix Molecular Designs | NCT04115306 Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Metastatic Breast Cancer | active not recruiting | 61 |
| 2026-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04344158 A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma (HCC) | active not recruiting | 648 |
| 2026-12 est. | P3 | Inmunotek S.L. | NCT04435990 Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites | Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic | recruiting | 150 |
| 2026-12 est. | P2/P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | active not recruiting | 501 |
| 2026-12 est. | P1/P2 | Sapience Therapeutics | NCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain | active not recruiting | 125 |
| 2026-12 est. | P1/P2 | GE Healthcare | NCT04604782 A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | Myocardial Ischemia; Coronary Artery Disease | recruiting | 54 |
| 2026-12 est. | P3 | Gilead Sciences GILD | NCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | Metastatic Breast Cancer | active not recruiting | 331 |
| 2026-12 est. | P2/P3 | AbbVie ABBV | NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; Wet AMD; CNV; Neovascular AMD; Neovascular Ag | active not recruiting | 671 |
| 2026-12 est. | P2 | Ambrx, Inc. | NCT04829604 ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | HER2 Positive Metastatic Breast Cancer | active not recruiting | 72 |
| 2026-12 est. | P3 | Allist Pharmaceuticals, Inc. | NCT04853342 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small C | Non-small Cell Lung Carcinoma | recruiting | 318 |
| 2026-12 est. | P3 | Kedrion S.p.A. | NCT04944979 Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | Primary Immunodeficiency Disease | active not recruiting | 30 |
| 2026-12 est. | P3 | GC Cell Corporation | NCT04969731 Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | recruiting | 408 |
| 2026-12 est. | P2 | UBP Greater China (Shanghai) Co., Ltd | NCT04985890 A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir | HIV-1-infection | not yet recruiting | 20 |
| 2026-12 est. | P2 | Zenith Epigenetics | NCT04986423 ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | recruiting | 200 |
| 2026-12 est. | P1/P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma | recruiting | 170 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05054439 A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC | Head and Neck Squamous Cell Carcinoma | active not recruiting | 45 |
| 2026-12 est. | P2/P3 | DiaMedica Therapeutics Inc DMAC | NCT05065216 Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) | Acute Stroke; Ischemic Stroke; Stroke | recruiting | 728 |
| 2026-12 est. | P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05112991 Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | Advanced Endometrial Cancer | recruiting | 108 |
| 2026-12 est. | P2 | Sunshine Lake Pharma Co., Ltd. SBFM | NCT05139719 A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Dis | Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | recruiting | 110 |
| 2026-12 est. | P2 | Ascentage Pharma Group Inc. AAPG | NCT05147467 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | recruiting | 75 |
| 2026-12 est. | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT05170958 A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | Advanced Solid Tumor | recruiting | 396 |
| 2026-12 est. | P2 | Lion TCR Pte. Ltd. | NCT05195294 Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinoma | not yet recruiting | 55 |
| 2026-12 est. | P1/P2 | Rottapharm Biotech | NCT05205330 Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | Refractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Ca | active not recruiting | 107 |
| 2026-12 est. | P1/P2 | Denali Therapeutics Inc. DNLI | NCT05262023 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Deme | Frontotemporal Dementia | active not recruiting | 85 |
| 2026-12 est. | P2 | 3D Medicines | NCT05265052 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain | Cancer Pain | not yet recruiting | 177 |
| 2026-12 est. | P3 | Genelux Corporation GNLX | NCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primar | recruiting | 186 |
| 2026-12 est. | P1/P2 | Keymed Biosciences Co.Ltd | NCT05299424 A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | recruiting | 48 |
| 2026-12 est. | P2 | Aveta Biomics, Inc. | NCT05312710 Safety and Efficacy of APG-157 in Head and Neck Cancer | Head and Neck Cancer; Squamous Cell Carcinoma of Oral Cavity; Squamous Cell Carcinoma of the Orophar | active not recruiting | 24 |
| 2026-12 est. | P2 | TolerogenixX GmbH | NCT05365672 Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation | Kidney Transplantation | recruiting | 126 |
| 2026-12 est. | P1/P2 | Stemline Therapeutics, Inc. | NCT05386108 Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous Sy | recruiting | 73 |
| 2026-12 est. | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT05392114 A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | Hereditary Angioedema | active not recruiting | 154 |
| 2026-12 est. | P2 | Kite, A Gilead Company | NCT05396885 Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Multiple Myeloma | active not recruiting | 136 |
| 2026-12 est. | P3 | Suven Life Sciences Limited | NCT05397639 Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Agitation; Alzheimer's Type Dementia | active not recruiting | 375 |
| 2026-12 est. | P1/P2 | SynDevRx, Inc. | NCT05455619 Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer | HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer | recruiting | 52 |
| 2026-12 est. | P2 | Lantern Pharma Inc. LTRN | NCT05456256 A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung | recruiting | 90 |
| 2026-12 est. | P1/P2 | Step Pharma, SAS | NCT05463263 A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Lymphoma, B-Cell; Lymphoma, T-Cell | recruiting | 180 |
| 2026-12 est. | P1/P2 | AP Biosciences Inc. | NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion | Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squam | recruiting | 168 |
| 2026-12 est. | P1/P2 | Dren Bio | NCT05475925 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | LGLL - Large Granular Lymphocytic Leukemia; Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Primary C | recruiting | 200 |
| 2026-12 est. | P3 | RayzeBio, Inc. | NCT05477576 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Di | active not recruiting | 343 |
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05482568 A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | recruiting | 324 |
| 2026-12 est. | P3 | Madrigal Pharmaceuticals, Inc. MDGL | NCT05500222 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | NASH; Cirrhosis, Liver | active not recruiting | 845 |
| 2026-12 est. | P1/P2 | Monte Rosa Therapeutics, Inc GLUE | NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients | NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC | active not recruiting | 174 |
| 2026-12 est. | P2 | Sinew Pharma Inc. | NCT05557448 To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose | Hepatitis | recruiting | 24 |
| 2026-12 est. | P1/P2 | Eupraxia Pharmaceuticals Inc. EPRX | NCT05608681 A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). | Eosinophilic Esophagitis | recruiting | 117 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05623982 A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Non-hodgkin's Lymphoma | recruiting | 40 |
| 2026-12 est. | P1/P2 | OriCell Therapeutics Co., Ltd. | NCT05652920 Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | Hepatocellular Carcinoma | recruiting | 105 |
| 2026-12 est. | P3 | Mabscale, LLC | NCT05654454 A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | recruiting | 620 |
| 2026-12 est. | P1/P2 | In8bio Inc. INAB | NCT05664243 A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolom | Glioblastoma | active not recruiting | 4 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05668858 A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | active not recruiting | 70 |
| 2026-12 est. | P1/P2 | Akeso | NCT05689853 Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | Solid Tumor, Adult | recruiting | 87 |
| 2026-12 est. | P2 | Amydis Inc. | NCT05709314 A Study of AMDX-2011P in Participants With CAA | Cerebral Amyloid Angiopathy | recruiting | 25 |
| 2026-12 est. | P2 | Taiho Oncology, Inc. | NCT05727176 Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement | recruiting | 120 |
| 2026-12 est. | P1/P2 | A2 Biotherapeutics Inc. | NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | Solid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Small | active not recruiting | 160 |
| 2026-12 est. | P2 | Zucara Therapeutics Inc. | NCT05762107 A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Type 1 Diabetes Mellitus With Hypoglycemia | recruiting | 186 |
| 2026-12 est. | P3 | Cook MyoSite | NCT05776277 Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury | Fecal Incontinence | active not recruiting | 200 |
| 2026-12 est. | P2/P3 | ReAlta Life Sciences, Inc. | NCT05778188 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Und | Hypoxic-Ischemic Encephalopathy | recruiting | 173 |
| 2026-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05780567 Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Canc | Breast Cancer | active not recruiting | 1946 |
| 2026-12 est. | P1/P2 | TiumBio Co., Ltd. | NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | Solid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer | recruiting | 140 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05785039 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors | Urinary System Tumor; Solid Tumor | recruiting | 76 |
| 2026-12 est. | P1/P2 | Tern Therapeutics, LLC | NCT05791864 A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease | Neuronal Ceroid Lipofuscinosis Type 2 | recruiting | 26 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05803018 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies | Gynecological Malignant Tumor; Solid Tumor | recruiting | 38 |
| 2026-12 est. | P1/P2 | GeneCradle Inc | NCT05824169 Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients | Spinal Muscular Atrophy | recruiting | 18 |
| 2026-12 est. | P2 | Protara Therapeutics TARA | NCT05871970 Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age | Lymphatic Malformation | recruiting | 38 |
| 2026-12 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05884255 An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | Advanced Gastroenteropancreatic Neuroendocrine Tumor | recruiting | 220 |
| 2026-12 est. | P1/P2 | Beam Therapeutics Inc. BEAM | NCT05885464 A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL | Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia | active not recruiting | 5 |
| 2026-12 est. | P1/P2 | Guangzhou Gloria Biosciences Co., Ltd. | NCT05909436 Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors | Solid Tumor | recruiting | 107 |
| 2026-12 est. | P2 | Alto Neuroscience ANRO | NCT05922878 Study of ALTO-300 in MDD | Major Depressive Disorder | recruiting | 325 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05924841 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer | Small Cell Lung Cancer | recruiting | 100 |
| 2026-12 est. | P1/P2 | BioCardia, Inc. BCDA | NCT05925608 Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells | Heart Failure, Systolic | active not recruiting | 39 |
| 2026-12 est. | P3 | TransThera Sciences (Nanjing), Inc. | NCT05948475 Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Cholangiocarcinoma | active not recruiting | 200 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05949606 A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | active not recruiting | 95 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05956587 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tum | Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma | recruiting | 121 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05965856 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | Urothelial Carcinoma; Solid Tumor | recruiting | 52 |
| 2026-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05987358 A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma. | Biliary Carcinoma | active not recruiting | 165 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05990803 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies | Cervical Cancer | recruiting | 130 |
| 2026-12 est. | P2 | Aadi Bioscience, Inc. | NCT05997017 Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Endometrial Cancer; Endometrioid Tumor; Cancer; Tumor; Recurrent Endometrial Carcinoma; Endometrioid | recruiting | 29 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06006169 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | Head and Neck Squamous Cell Carcinoma | recruiting | 186 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06008054 A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Co | Esophageal Cancer; Gastric Cancer; Colorectal Cancer | recruiting | 376 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06031584 A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestina | Her2-positive/Low-expression Urinary and Digestive Tract Tumors | recruiting | 42 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06042894 A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer | Breast Cancer | recruiting | 58 |
| 2026-12 est. | P2 | NS Pharma, Inc. | NCT06046222 Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | Eosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndrome | active not recruiting | 45 |
| 2026-12 est. | P1/P2 | Institut de Recherches Internationales Servier (I.R.I.S.) | NCT06052813 A Study of BN104 in the Treatment of Acute Leukemia | ALL, Adult; AML, Adult; Acute Leukaemia; KMT2A Rearrangement; NPM1 Mutation; NUP98 Gene Rearrangemen | active not recruiting | 66 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06066203 A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | Non-hodgkin's Lymphoma | recruiting | 40 |
| 2026-12 est. | P2 | Frantz Viral Therapeutics, LLC | NCT06075264 Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) | Vulvar Diseases; HPV Infection; Vulvar HSIL; Pre-Cancerous Dysplasia; HPV Disease; VIN, Usual Type; | recruiting | 27 |
| 2026-12 est. | P2 | Panafina, Inc. | NCT06080789 A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis | Acute Pancreatitis | recruiting | 36 |
| 2026-12 est. | P1/P2 | Nexcella Inc. | NCT06097832 Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Light Chain (AL) Amyloidosis | active not recruiting | 45 |
| 2026-12 est. | P2 | AbbVie ABBV | NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Met | Unresectable Metastatic Colorectal Cancer | active not recruiting | 280 |
| 2026-12 est. | P1/P2 | Lexeo Therapeutics LXEO | NCT06109181 Gene Therapy for ACM Due to a PKP2 Pathogenic Variant | Arrhythmogenic Cardiomyopathy; PKP2-ACM; PKP2-ARVC | active not recruiting | 10 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06114511 A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | active not recruiting | 78 |
| 2026-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06122831 A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) | Myelofibrosis | recruiting | 92 |
| 2026-12 est. | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06132893 A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Focal Epilepsy | active not recruiting | 390 |
| 2026-12 est. | P1/P2 | Bivision Pharmaceuticals, Inc. | NCT06139575 Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | Prostate Cancer | recruiting | 90 |
| 2026-12 est. | P1/P2 | Xenothera SAS | NCT06154291 FIH XON7 in Advanced/Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Cancer | recruiting | 255 |
| 2026-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies | recruiting | 154 |
| 2026-12 est. | P3 | Boryung Pharmaceutical Co., Ltd | NCT06220773 A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | Essential Hypertension; Type 2 Diabetes Mellitus | recruiting | 276 |
| 2026-12 est. | P2/P3 | RemeGen Co., Ltd. | NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therap | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | recruiting | 90 |
| 2026-12 est. | P1/P2 | Alyssum Therapeutics | NCT06234098 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refra | Solid Tumor | recruiting | 100 |
| 2026-12 est. | P1/P2 | Sichuan Huiyu Pharmaceutical Co., Ltd | NCT06243354 Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation | Safety; Tolerability; Efficacy | recruiting | 257 |
| 2026-12 est. | P2 | Eikon Therapeutics EIKN | NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | NSCLC | active not recruiting | 70 |
| 2026-12 est. | P1/P2 | Songqi Gao | NCT06262139 Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients | MRI Scan | recruiting | 12 |
| 2026-12 est. | P3 | Pacira Pharmaceuticals, Inc PCRX | NCT06269705 ZILRETTA in Subjects With Shoulder Osteoarthritis | Glenohumeral Osteoarthritis | active not recruiting | 150 |
| 2026-12 est. | P3 | Gossamer Bio USA, Inc. GOSS | NCT06274801 Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | Pulmonary Arterial Hypertension | recruiting | 330 |
| 2026-12 est. | P1/P2 | Latticon Antibody Therapeutics, Inc | NCT06277219 A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) | Advanced Solid Tumor | recruiting | 150 |
| 2026-12 est. | P2 | Omeros Corporation OMER | NCT06298955 Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | active not recruiting | 25 |
| 2026-12 est. | P2 | Kind Pharmaceuticals LLC | NCT06302491 A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia | β -Thalassemia | recruiting | 64 |
| 2026-12 est. | P2 | Kind Pharmaceuticals LLC | NCT06304103 A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome | Myelodysplastic Syndromes | recruiting | 63 |
| 2026-12 est. | P2 | Zhejiang Haichang Biotech Co., Ltd. | NCT06309485 Phase 2 Study of WGI-0301 for Advanced HCC | Advanced Hepatocellular Carcinoma (HCC) | recruiting | 60 |
| 2026-12 est. | P1/P2 | Theravectys S.A. | NCT06319963 A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | HPV-Related Cervical Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma | recruiting | 72 |
| 2026-12 est. | P2 | Sound Pharmaceuticals, Incorporated SOGP | NCT06340633 SPI-1005 in Adults Receiving Cochlear Implant | Hearing Loss; Cochlear Trauma | recruiting | 40 |
| 2026-12 est. | P2 | ReAlta Life Sciences, Inc. | NCT06343792 Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease | Steroid Refractory GVHD | recruiting | 66 |
| 2026-12 est. | P1/P2 | Beijing Scitech-Mq Pharmaceuticals Limited | NCT06359860 A Study of ST-1898 for Unresectable or Metastatic Melanoma | Unresectable or Metastatic Melanoma | active not recruiting | 64 |
| 2026-12 est. | P3 | Octapharma | NCT06361537 Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of A | Acute Hereditary Angio Edema | recruiting | 124 |
| 2026-12 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06382129 A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | Non-small Cell Lung Cancer | active not recruiting | 698 |
| 2026-12 est. | P1/P2 | GeneCradle Inc | NCT06391736 Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug | Pompe Disease (Late-onset) | recruiting | 33 |
| 2026-12 est. | P1/P2 | 858 Therapeutics, Inc. | NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovar | recruiting | 120 |
| 2026-12 est. | P2 | NoNO Inc. | NCT06403267 NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy | Acute Ischemic Stroke | recruiting | 600 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06405425 A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | Urothelial Carcinoma | recruiting | 52 |
| 2026-12 est. | P3 | Axsome Therapeutics, Inc. AXSM | NCT06413433 Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | Binge-Eating Disorder | recruiting | 450 |
| 2026-12 est. | P2 | NMD Pharma A/S | NCT06414954 Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | Myasthenia Gravis; Myasthenia Gravis, MuSK | recruiting | 84 |
| 2026-12 est. | P2 | Highlight Therapeutics | NCT06422936 Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) | Basal Cell Carcinoma | active not recruiting | 50 |
| 2026-12 est. | P1/P2 | Georgiamune Inc | NCT06425926 Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Melanoma Stage IV; Solid Tumor | recruiting | 117 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06437509 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer | Extensive-stage Small-cell Lung Cancer | recruiting | 66 |
| 2026-12 est. | P2 | Biohaven Therapeutics Ltd. BHVN | NCT06443463 Long-term Safety and Tolerability of BHV-7000 | Focal Epilepsy | enrolling by invitation | 660 |
| 2026-12 est. | P3 | Prove pharm | NCT06448143 Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients | Ureter Injury | not yet recruiting | 18 |
| 2026-12 est. | P2 | Abivax S.A. ABVX | NCT06456593 Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | Moderately to Severely Active Crohn Disease | recruiting | 212 |
| 2026-12 est. | P3 | AbbVie ABBV | NCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | active not recruiting | 1400 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06471205 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer | Triple-negative Breast Cancer | recruiting | 52 |
| 2026-12 est. | P2 | Shanghai BDgene Co., Ltd. | NCT06474442 A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis | Herpes Simplex Virus Type I Stromal Keratitis | recruiting | 40 |
| 2026-12 est. | P3 | VIS, Inc. | NCT06487897 Phase III Presbyopia Correction Using the VIS Opti-K™ System | Presbyopia | recruiting | 75 |
| 2026-12 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06500026 A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | Small Cell Lung Cancer | active not recruiting | 722 |
| 2026-12 est. | P1/P2 | Meribank Biotech Co., Ltd. | NCT06501066 Mesenchymal Stem Cells for Frailty Syndrome | Pathologic Processes | active not recruiting | 66 |
| 2026-12 est. | P1/P2 | SCG Cell Therapy Pte. Ltd. | NCT06505551 Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | HPV-Related Squamous Cell Carcinoma; HPV-Related Cervical Squamous Cell Carcinoma; HPV-Related Vulva | not yet recruiting | 66 |
| 2026-12 est. | P3 | Nanjing Chia-tai Tianqing Pharmaceutical | NCT06512363 A Study of Ramelteon in Chinese Patients With Chronic Insomnia | Chronic Insomnia | not yet recruiting | 280 |
| 2026-12 est. | P2 | Ryvu Therapeutics SA | NCT06534437 MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | Non-Hodgkin Lymphoma, B-cell | recruiting | 178 |
| 2026-12 est. | P2 | Dianthus Therapeutics DNTH | NCT06537999 A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy | active not recruiting | 46 |
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06568094 A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | Prostate Cancer | recruiting | 100 |
| 2026-12 est. | P3 | Axsome Therapeutics, Inc. AXSM | NCT06568367 Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | Excessive Sleepiness; Shift-work Disorder | recruiting | 520 |
| 2026-12 est. | P3 | MediWound Ltd MDWD | NCT06568627 A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) | Venous Leg Ulcer (VLU) | recruiting | 216 |
| 2026-12 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06569524 Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) | Non-alcoholic Steatohepatitis | recruiting | 120 |
| 2026-12 est. | P3 | Wuxi Cellular Biopharmaceutical Group Ltd. | NCT06570291 Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis | Knee Osteoarthritis | recruiting | 520 |
| 2026-12 est. | P2 | Angitia Biopharmaceuticals | NCT06577935 A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | Postmenopausal Osteoporosis | active not recruiting | 379 |
| 2026-12 est. | P2 | Sunhawk Vision Biotech, Inc. | NCT06579287 A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | Myopia, Progressive | active not recruiting | 140 |
| 2026-12 est. | P2/P3 | iCoat Medical AB | NCT06582485 A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys | Ischemia-reperfusion Injury; Kidney Transplant; Complications | not yet recruiting | 200 |
| 2026-12 est. | P3 | Dr. Falk Pharma GmbH | NCT06596252 Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | Eosinophilic Esophagitis | active not recruiting | 308 |
| 2026-12 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06605222 A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 201 |
| 2026-12 est. | P2 | Delcath Systems Inc. DCTH | NCT06607458 Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Appr | Refractory Metastatic Colorectal Cancer | recruiting | 90 |
| 2026-12 est. | P2 | Filament Health Corp. | NCT06608459 PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study | Opioid Use Disorder | not yet recruiting | 10 |
| 2026-12 est. | P1/P2 | LaNova Medicines Limited | NCT06650566 Study of LM-299 in Subjects Advanced Malignant Tumors | Malignant Tumors | recruiting | 108 |
| 2026-12 est. | P1/P2 | Ranok Therapeutics (Hangzhou) Co., Ltd. | NCT06667544 A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation | KRAS G12D Mutation | recruiting | 152 |
| 2026-12 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06671379 A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | Non-small Cell Lung Cancer | active not recruiting | 498 |
| 2026-12 est. | P1/P2 | Technophage, SA | NCT06677229 Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury | Acute Spinal Cord Injury (SCI) | recruiting | 28 |
| 2026-12 est. | P1/P2 | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | NCT06677255 A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment | Steroid-refractory Acute Graft-versus-host Disease | not yet recruiting | 149 |
| 2026-12 est. | P3 | TR Therapeutics | NCT06707103 Tissue Repair Gel in Venous Leg Ulcers in AU/US | Venous Leg Ulcer; Venous Ulcer; Venous Stasis Ulcer; Venous Stasis; Wound Heal; Wound; Venous Insuff | recruiting | 312 |
| 2026-12 est. | P2 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | NCT06707883 A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | active not recruiting | 258 |
| 2026-12 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients Wi | Non-Small Cell Lung Cancer | active not recruiting | 432 |
| 2026-12 est. | P2/P3 | Napo Pharmaceuticals, Inc. | NCT06721871 Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) | Microvillus Inclusion Disease; Congenital Disorders; Rare Diseases | active not recruiting | 6 |
| 2026-12 est. | P2 | Shandong New Time Pharmaceutical Co., LTD | NCT06722950 Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy | Colorectal Adenoma | not yet recruiting | 120 |
| 2026-12 est. | P2 | Centessa Pharmaceuticals (UK) Limited | NCT06752668 A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia | recruiting | 248 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06754644 A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | NSCLC | recruiting | 808 |
| 2026-12 est. | P3 | Akeso | NCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | Triple-Negative Breast Cancer (TNBC) | recruiting | 416 |
| 2026-12 est. | P3 | Azidus Brasil | NCT06817096 Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza | Covid 19; Influenza | not yet recruiting | 340 |
| 2026-12 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06820099 Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity | Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesi | recruiting | 225 |
| 2026-12 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | Ovarian Cancer | recruiting | 150 |
| 2026-12 est. | P3 | Astria Therapeutics, Inc. | NCT06842823 A Study of Navenibart in Participants With Hereditary Angioedema | Hereditary Angioedema (HAE) | active not recruiting | 157 |
| 2026-12 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06844474 A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC | NSCLC | recruiting | 300 |
| 2026-12 est. | P2 | Dogwood Therapeutics Inc. DWTX | NCT06848348 Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | Chemotherapy Induced Neuropathic Pain; Chemotherapy Induced Pain Neuropathy; Chemotherapy Induced Pa | active not recruiting | 240 |
| 2026-12 est. | P2 | Cardiac Success | NCT06851949 Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure | Heart Failure With Reduced Ejection Fraction | recruiting | 20 |
| 2026-12 est. | P1/P2 | Regenerative Ocular Immunobiologics LLC | NCT06852768 Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD) | oGHVD | active not recruiting | 15 |
| 2026-12 est. | P3 | Sound Pharmaceuticals, Incorporated SOGP | NCT06859788 SPI-1005 for the Treatment of Meniere's Disease (Open Label) | Meniere's Disease; Ménière's Disease | active not recruiting | 200 |
| 2026-12 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06859931 Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | not yet recruiting | 120 |
| 2026-12 est. | P1/P2 | Design Therapeutics, Inc. DSGN | NCT06874010 A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia | Friedreich Ataxia | recruiting | 20 |
| 2026-12 est. | P2 | Jina Pharmaceuticals Inc. | NCT06890832 A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | Metastatic Castration-resistant Prostate Cancer, MCRPC | not yet recruiting | 75 |
| 2026-12 est. | P2 | jCyte, Inc | NCT06912633 Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) | Retinitis Pigmentosa | active not recruiting | 31 |
| 2026-12 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06915142 A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour | Advanced Malignant Tumour | recruiting | 300 |
| 2026-12 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06942767 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophag | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | not yet recruiting | 100 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2026-12 est. | P3 | Veradermics, Inc. MANE | NCT06972264 Safety and Efficacy of VDPHL01 in Males With AGA | Androgenetic Alopecia; AGA; Male Pattern Baldness | active not recruiting | 480 |
| 2026-12 est. | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06974851 A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | Bstructive Sleep Apnea (OSA) and Obesity | recruiting | 140 |
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06974929 A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer | Breast Cancer | recruiting | 80 |
| 2026-12 est. | P2 | Ryvu Therapeutics SA | NCT06987058 RVU120 Rollover Study | Advanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndrome | enrolling by invitation | 14 |
| 2026-12 est. | P3 | Minghui Pharmaceutical (Hangzhou) Ltd | NCT06989918 MHB018A Treatment in Patients With Active Thyroid Eye Disease | Thyroid Associated Ophthalmopathies | active not recruiting | 108 |
| 2026-12 est. | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06994650 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With O | Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy | active not recruiting | 144 |
| 2026-12 est. | P1/P2 | Krystal Biotech, Inc. KRYS | NCT06999733 A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | Neurotrophic Keratitis | recruiting | 60 |
| 2026-12 est. | P3 | Praxis Precision Medicines PRAX | NCT07010471 A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | Developmental and Epileptic Encephalopathy 1 | active not recruiting | 160 |
| 2026-12 est. | P3 | Krystal Biotech, Inc. KRYS | NCT07016750 A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epide | recruiting | 16 |
| 2026-12 est. | P3 | Praxis Precision Medicines PRAX | NCT07019922 A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | Epileptic Encephalopathy; SCN2A Encephalopathy | recruiting | 40 |
| 2026-12 est. | P2 | Imbria Pharmaceuticals, Inc. | NCT07023614 A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | recruiting | 165 |
| 2026-12 est. | P2 | iRegene Therapeutics Co., Ltd. | NCT07028632 The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | Parkinson Disease (PD) | not yet recruiting | 30 |
| 2026-12 est. | P3 | Atea Pharmaceuticals, Inc. AVIR | NCT07037277 C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection; Hepatitis C | active not recruiting | 880 |
| 2026-12 est. | P3 | Kedrion S.p.A. | NCT07059000 A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | Chronic Primary Immune Thrombocytopenia (ITP) | recruiting | 40 |
| 2026-12 est. | P2 | Galderma R&D | NCT07074977 Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) | Chronic Pruritus of Unknown Origin | active not recruiting | 50 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07089186 Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Comp | recruiting | 80 |
| 2026-12 est. | P3 | Celltrion | NCT07093476 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | T2DM; Diabete Type 2; DM | recruiting | 171 |
| 2026-12 est. | P3 | Vir Biotechnology, Inc. VIR | NCT07128550 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | Viral Hepatitis | active not recruiting | 150 |
| 2026-12 est. | P1/P2 | Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. | NCT07136285 Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC | SCLC, Extensive Stage | recruiting | 27 |
| 2026-12 est. | P1/P2 | EicOsis Human Health Inc. | NCT07142044 Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study) | Parkinson's Disease (PD) | recruiting | 18 |
| 2026-12 est. | P1/P2 | One-carbon Therapeutics AB | NCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung | recruiting | 43 |
| 2026-12 est. | P2 | Eli Lilly and Company LLY | NCT07169851 A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions; Neoplasms | recruiting | 204 |
| 2026-12 est. | P3 | Otsuka Pharmaceutical Co., Ltd. | NCT07173478 A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | Atopic Dermatitis (AD) | not yet recruiting | 156 |
| 2026-12 est. | P2 | Avalyn Pharma Inc. AVLN | NCT07194382 AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | Idiopathic Pulmonary Fibrosis (IPF) | recruiting | 160 |
| 2026-12 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07198633 A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | Advanced Prostate Cancer | recruiting | 212 |
| 2026-12 est. | P2 | Elion Therapeutics, Inc. | NCT07215273 Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy | Invasive Mould Infection | recruiting | 60 |
| 2026-12 est. | P3 | Vanda Pharmaceuticals VNDA | NCT07221578 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Social Anxiety Disorder (SAD) | active not recruiting | 500 |
| 2026-12 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT07229950 A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease | Adult Patients With Moderately to Severely Active Ulcerative Colitis | recruiting | 48 |
| 2026-12 est. | P1/P2 | Ingenia Therapeutics INC | NCT07231679 A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease | Healthy Volunteers; Chronic Kidney Disease | recruiting | 94 |
| 2026-12 est. | P3 | Grand Shuyang Life Sciences (Chengdu) Co., Ltd. | NCT07233213 An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia (ITP) | recruiting | 36 |
| 2026-12 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Duc | not yet recruiting | 300 |
| 2026-12 est. | P2 | Dong-A ST Co., Ltd. | NCT07239440 Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have | Diabete Mellitus | not yet recruiting | 288 |
| 2026-12 est. | P2 | Ventus Therapeutics U.S., Inc. | NCT07260877 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult | Cutaneous Lupus Erythematosus (CLE); Systemic Lupus Erythematosus; SLE; SLE (Systemic Lupus); CLE | active not recruiting | 24 |
| 2026-12 est. | P2 | Novaliq GmbH | NCT07285070 Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis | Non-infectious Anterior Uveitis | active not recruiting | 20 |
| 2026-12 est. | P2/P3 | Intra-IMMUSG Pte Ltd | NCT07290088 Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients | Advanced Solid Cancers | recruiting | 52 |
| 2026-12 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07297797 Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension | Mild to Moderate Hypertension | active not recruiting | 238 |
| 2026-12 est. | P2 | Enveda Therapeutics | NCT07298395 Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis (AD) | recruiting | 105 |
| 2026-12 est. | P2 | Enveda Therapeutics | NCT07301255 ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults | Asthma | recruiting | 50 |
| 2026-12 est. | P2 | Henan Genuine Biotech Co., Ltd. | NCT07308782 A Phase Ⅱa Clinical Study of CL-197 Capsules | HIV-1 Infection | recruiting | 24 |
| 2026-12 est. | P2 | VapeAway | NCT07322432 The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | Addiction Nicotine | recruiting | 70 |
| 2026-12 est. | P2 | Pulmovant, Inc. | NCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | Pulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovas | recruiting | 20 |
| 2026-12 est. | P2 | Next Life Sciences | NCT07361120 Plan A Occlusion and Reversal System Feasibility Study | Fertility; Fertility, Male; Healthy Male Adults | recruiting | 40 |
| 2026-12 est. | P2 | Traws Pharma, Inc. TRAW | NCT07371650 This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza | Influenza | active not recruiting | 105 |
| 2026-12 est. | P2 | Toll Biotech Co. Ltd. (Beijing) | NCT07408024 Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis (RA) | recruiting | 24 |
| 2026-12 est. | P2 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | NCT07413094 Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | Sepsis | recruiting | 309 |
| 2026-12 est. | P1/P2 | PT. Prodia Stem Cell Indonesia | NCT07439848 Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis | Acute Respiratory Distress Syndrome | recruiting | 15 |
| 2026-12 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07472725 A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled | Diabetes Mellitus, Type 2 | active not recruiting | 102 |
| 2026-12 est. | P2 | Enanta Pharmaceuticals, Inc ENTA | NCT07482657 A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Vir | RSV Infection; RSV; Respiratory Syncytial Virus (RSV) | recruiting | 150 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07487103 Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes | Type 2 Diabetes | not yet recruiting | 478 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07489586 A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | not yet recruiting | 356 |
| 2026-12 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT07489612 QLS1410 in Participants With Uncontrolled Hypertension | Hypertension (HTN) | enrolling by invitation | 260 |
| 2026-12 est. | P3 | Vergent Bioscience, Inc. | NCT07499674 Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | Lung Cancer; Lung Metastases | recruiting | 132 |
| 2026-12 est. | P2 | Kardigan, Inc. KARD | NCT07511361 Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension | Hypertension; Acute Severe Hypertension; Hypertensive Emergency; Hypertensive Urgency | recruiting | 140 |
| 2026-12 est. | P2 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | NCT07513454 A Phase 2 Study of HW211026 | Actinic Keratosis | not yet recruiting | 80 |
| 2026-12 est. | P2/P3 | Oculis OCS | NCT07548632 A Clinical Study Evaluating Licaminlimab for Dry Eye Disease | Dry Eye Disease (DED) | active not recruiting | 160 |
| 2026-12 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT07576608 A Phase II Study of 9MW3811 in Patients With Pathological Scar | Scar | recruiting | 30 |
| 2026-12 est. | P2 | Chengdu Suncadia Medicine Co., Ltd. | NCT07613866 A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | not yet recruiting | 190 |
| 2026-12 est. | P3 | Chengdu Kangnuoxing Biopharma,Inc. | NCT07678931 Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis (SAR) | recruiting | 136 |
| 2026-12 est. | P3 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07688772 A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | active not recruiting | 220 |
| 2026-12 est. | P1/P2 | Heron Neutron Medical Corp. | NCT07691775 A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors | Solid Tumor | recruiting | 30 |
| 2026-12 est. | P2 | Connect Biopharm LLC CNTB | NCT07705737 Rademikibart IV for Acute Asthma and COPD Exacerbation | Asthma Acute; COPD Exacerbation Acute | recruiting | 40 |
| 2026-12 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07709897 A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting | Prevention of Postoperative Nausea and Vomiting | recruiting | 260 |
| 2026-12 est. | P3 | Harrow Inc HROW | NCT07832552 A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surg | Postoperative Ocular Inflammation; Postoperative Ocular Pain | enrolling by invitation | 250 |
| 2026-12 est. | P2 | Thiogenesis Therapeutics, Inc. TTIPF | NCT07837726 Pilot Study of TTI-0102 in Cystinosis | Nephropathic Cystinosis; Cystinosis | not yet recruiting | 6 |
| 2026-12 est. | P1/P2 | Danisco | NCT07893288 A Study of Single and Combination Lipase Dietary Supplements to Increase Fatty Acid Absorption in Generally Health Adults | Digestive Symptoms; Gastrointestinal Symptoms; Healthy; Impaired Pancreatic Function | not yet recruiting | 50 |
| 2026-12 est. | P2/P3 | Dexa Medica Group | NCT07937462 The Efficacy and Safety of DLBS1442 in Patients With Primary Dysmenorrhea | Primary Dysmenorrhea | recruiting | 210 |
| 2026-12-01 est. | P3 | Janssen Research & Development, LLC | NCT03767244 A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | Prostatic Neoplasms | active not recruiting | 2517 |
| 2026-12-01 est. | P2 | Intra-IMMUSG Pte Ltd | NCT04452955 A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors | Solid Tumor | active not recruiting | 51 |
| 2026-12-01 est. | P2 | EpicentRx, Inc. | NCT04673942 A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | Solid Tumor, Adult; Cancer; Neoplasms; Sarcoma; Sarcoma,Soft Tissue; Chondrosarcoma | active not recruiting | 140 |
| 2026-12-01 est. | P3 | Octapharma | NCT04918173 Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery | Congenital Antithrombin Deficiency | recruiting | 38 |
| 2026-12-01 est. | P2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | NCT05128825 A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | recruiting | 310 |
| 2026-12-01 est. | P2/P3 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05860465 Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | Locally Advanced or Metastatic Breast Cancer | recruiting | 254 |
| 2026-12-01 est. | P3 | Tasly Pharmaceutical Group Co., Ltd | NCT06000956 A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo | Ankylosing Spondylitis | recruiting | 408 |
| 2026-12-01 est. | P2 | Cartesian Therapeutics RNAC | NCT06038474 Descartes-08 for Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | active not recruiting | 6 |
| 2026-12-01 est. | P1/P2 | FindCure Biosciences (ZhongShan) Co., Ltd. | NCT06499350 A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors | Advanced Malignant Solid Tumors | recruiting | 33 |
| 2026-12-01 est. | P1/P2 | AP Biosciences Inc. | NCT06669975 A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 85 |
| 2026-12-01 est. | P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT06683703 Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases | Non-small Cell Lung Cancer Patients with Brain Metastases | not yet recruiting | 118 |
| 2026-12-01 est. | P3 | Biogen BIIB | NCT06685757 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) | Antibody-mediated Rejection | active not recruiting | 132 |
| 2026-12-01 est. | P3 | Shanghai Vitalgen BioPharma Co., Ltd. | NCT06699108 Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy | Bietti Crystalline Dystrophy; Inherited Retinal Diseases | active not recruiting | 45 |
| 2026-12-01 est. | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06838000 Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, a | Pneumococcal Infections | active not recruiting | 1268 |
| 2026-12-01 est. | P1/P2 | CellARTs Inc. | NCT06841861 Spermatogonial Differentiation Via Testicular Organoid | Infertility, Male; Gene Abnormality; Sterility, Male | recruiting | 100 |
| 2026-12-01 est. | P2 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT06858618 FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms | Safety; Antitumor Activity; PK Profile | active not recruiting | 47 |
| 2026-12-01 est. | P1/P2 | Sanofi SNY | NCT06907511 Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain | Pandemic Influenza Immunization; Healthy Volunteers | active not recruiting | 720 |
| 2026-12-01 est. | P2/P3 | HealthBio, Inc. | NCT06974084 A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Mara | Long COVID | not yet recruiting | 252 |
| 2026-12-01 est. | P3 | Virchow Group | NCT07017036 Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients | Primary Immunodeficiency Diseases (PID) | not yet recruiting | 44 |
| 2026-12-01 est. | P3 | Fujian Akeylink Biotechnology Co., Ltd. | NCT07090759 To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Anti | Chronic Hepatitis b | recruiting | 526 |
| 2026-12-01 est. | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT07139535 A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | T2DM | not yet recruiting | 350 |
| 2026-12-01 est. | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT07139548 A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | T2DM | not yet recruiting | 600 |
| 2026-12-01 est. | P1/P2 | ASTEROGENE Biomedical Co. Ltd. | NCT07168603 EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease | Intervertebral Disc Degeneration | recruiting | 12 |
| 2026-12-01 est. | P3 | JYAMS PET Research & Development Limited | NCT07422857 Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function | Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia | recruiting | 316 |
| 2026-12-01 est. | P3 | Vanda Pharmaceuticals VNDA | NCT07446439 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Nausea and Vomiting; Obesity | recruiting | 280 |
| 2026-12-02 est. | P3 | Pfizer PFE | NCT07029711 A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | Severe Alopecia Areata | active not recruiting | 208 |
| 2026-12-03 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06421636 A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participant | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | active not recruiting | 19 |
| 2026-12-03 est. | P2 | Eisai Inc. | NCT06602258 A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | Alzheimer's Disease | active not recruiting | 105 |
| 2026-12-03 est. | P2 | Novartis Pharmaceuticals NVS | NCT06991556 An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Metastatic Hormone-sensitive Prostate Cancer | active not recruiting | 168 |
| 2026-12-04 est. | P3 | Pfizer PFE | NCT07500506 A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | Lyme Disease | recruiting | 1712 |
| 2026-12-05 est. | P1/P2 | Suzhou Forlong Biotechnology Co., Ltd | NCT07131202 A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 130 |
| 2026-12-05 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07616700 A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy | IgA Nephropathy (IgAN) | recruiting | 73 |
| 2026-12-07 est. | P3 | Alexion Pharmaceuticals, Inc. | NCT06724809 Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | NMOSD; Neuromyelitis Optica Spectrum Disorders | active not recruiting | 21 |
| 2026-12-08 est. | P3 | Janssen Research & Development, LLC | NCT05757869 A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | Atrial Fibrillation | active not recruiting | 20284 |
| 2026-12-08 est. | P2 | Pfizer PFE | NCT07228390 A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradeniti | Hidradenitis Suppurativa | active not recruiting | 128 |
| 2026-12-09 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT06126224 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | Psychosis Associated With Alzheimer's Disease | recruiting | 500 |
| 2026-12-09 est. | P1/P2 | SK Bioscience Co., Ltd. | NCT07280858 A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adult | Healthy Participants; Sarbecovirus | active not recruiting | 368 |
| 2026-12-10 est. | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05686642 Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke | Acute Ischemic Stroke | recruiting | 300 |
| 2026-12-10 est. | P3 | Boehringer Ingelheim | NCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standar | Lung Cancer, Non-squamous, Non-small Cell | active not recruiting | 428 |
| 2026-12-10 est. | P2 | AstraZeneca AZN | NCT07222917 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Ki | Chronic Kidney Disease and Hypertension | active not recruiting | 222 |
| 2026-12-11 est. | P2 | GlaxoSmithKline | NCT03441113 Extended Access of Momelotinib in Adults With Myelofibrosis | Primary Myelofibrosis | active not recruiting | 237 |
| 2026-12-11 est. | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT04879329 A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Urothelial Carcinoma | recruiting | 372 |
| 2026-12-12 est. | P2 | Ausper Biopharma Co., Ltd. | NCT07137910 A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) | Chronic Hepatitis B | recruiting | 200 |
| 2026-12-12 est. | P2 | Beijing QL Biopharmaceutical Co.,Ltd | NCT07230132 Efficacy and Safety of ZT006 in Overweight and Obese Participants | Overweight , Obesity | active not recruiting | 184 |
| 2026-12-12 est. | P3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT07376382 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC | NSCLC | not yet recruiting | 680 |
| 2026-12-12 est. | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07729475 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events | Elevated Lipoprotein(a) | not yet recruiting | 120 |
| 2026-12-13 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04957550 To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis | Psoriatic Arthritis | active not recruiting | 418 |
| 2026-12-14 est. | P2 | Bristol-Myers Squibb BMY | NCT06122779 Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure | active not recruiting | 227 |
| 2026-12-14 est. | P2 | GlaxoSmithKline | NCT06317311 A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | Carcinoma | active not recruiting | 41 |
| 2026-12-14 est. | P3 | Amgen AMGN | NCT06430866 Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | active not recruiting | 163 |
| 2026-12-14 est. | P3 | GlaxoSmithKline | NCT06806137 A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose | Chickenpox | recruiting | 600 |
| 2026-12-14 est. | P2 | Novo Nordisk A/S NVO | NCT07184632 A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity | Overweight; Obesity | active not recruiting | 224 |
| 2026-12-14 est. | P2 | Beijing Tide Pharmaceutical Co., Ltd | NCT07543796 Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb) | Postoperative Analgesia After Unilateral Hip Arthroplasty | recruiting | 200 |
| 2026-12-15 est. | P3 | Gedeon Richter Plc. | NCT03817502 Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | Schizophrenia | recruiting | 330 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-15 est. | P2/P3 | Janssen Research & Development, LLC | NCT05327114 Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | recruiting | 201 |
| 2026-12-15 est. | P1/P2 | GV20 Therapeutics | NCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma; | recruiting | 365 |
| 2026-12-15 est. | P3 | Exelixis EXEL | NCT05678673 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | Non-Clear Cell Renal Cell Carcinoma | active not recruiting | 317 |
| 2026-12-15 est. | P1/P2 | PLL TX AUSTRALIA PTY LTD | NCT06513546 A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients | Amyotrophic Lateral Sclerosis; ALS | not yet recruiting | 153 |
| 2026-12-15 est. | P3 | Alexion Pharmaceuticals, Inc. | NCT06607627 PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | Generalized Myasthenia Gravis; gMG | recruiting | 12 |
| 2026-12-15 est. | P2 | EXACT Therapeutics AS | NCT06850623 Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer | Locally Advanced Pancreatic Adenocarcinoma | recruiting | 25 |
| 2026-12-15 est. | P2 | Cerus Corporation CERS | NCT07015437 A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1 | Healthy Subjects | recruiting | 120 |
| 2026-12-15 est. | P3 | Ipsen | NCT07427797 A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | Moderate to Severe Glabellar Lines | active not recruiting | 309 |
| 2026-12-15 est. | P3 | Ipsen | NCT07435428 A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | Moderate to Severe Glabellar Lines | active not recruiting | 1300 |
| 2026-12-16 est. | P3 | Hoffmann-La Roche | NCT05503264 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Re | NMDAR Autoimmune Encephalitis; LGI1 Autoimmune Encephalitis | active not recruiting | 122 |
| 2026-12-16 est. | P3 | Shanghai JMT-Bio Inc. | NCT06747338 A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | Early or Locally Advanced HER2-positive Breast Cancer | active not recruiting | 520 |
| 2026-12-17 est. | P2 | Bristol-Myers Squibb BMY | NCT06268886 Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | Alzheimer Disease, Early Onset | active not recruiting | 310 |
| 2026-12-17 est. | P3 | Ipsen | NCT06730061 A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | Primary Biliary Cholangitis | active not recruiting | 18 |
| 2026-12-17 est. | P2 | Sanofi SNY | NCT06958536 A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease | Crohn's Disease | recruiting | 99 |
| 2026-12-17 est. | P2 | Sanofi SNY | NCT06975722 A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 105 |
| 2026-12-17 est. | P3 | Takeda TAK | NCT07363720 A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy | active not recruiting | 98 |
| 2026-12-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | NCT06062810 Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms | Breast Cancer | active not recruiting | 600 |
| 2026-12-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT07145333 Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms | SCLC | active not recruiting | 600 |
| 2026-12-18 est. | P3 | Ausper Biopharma Co., Ltd. | NCT07246889 Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | Chronic Hepatitis B | active not recruiting | 577 |
| 2026-12-20 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07158268 A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | not yet recruiting | 220 |
| 2026-12-20 est. | P3 | TJ Biopharma Co., Ltd. | NCT07208058 A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Dis | Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis | recruiting | 30 |
| 2026-12-21 est. | P3 | UCB Biopharma SRL | NCT06921850 A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | active not recruiting | 43 |
| 2026-12-22 est. | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT05468697 A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LI | Renal Cell Carcinoma | active not recruiting | 60 |
| 2026-12-22 est. | P2 | Janssen Pharmaceutica N.V., Belgium | NCT06544616 A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | Alzheimer Disease | active not recruiting | 55 |
| 2026-12-22 est. | P2 | Boehringer Ingelheim | NCT06769048 A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Geographic Atrophy | active not recruiting | 150 |
| 2026-12-22 est. | P3 | Adverum Biotechnologies, Inc. | NCT06856577 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD | active not recruiting | 311 |
| 2026-12-22 est. | P3 | Taisho Pharmaceutical Co., Ltd. | NCT07285291 A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | Hyperphosphatemia Patients on Hemodialysis | recruiting | 100 |
| 2026-12-22 est. | P2 | Healthgen Biotechnology Corp. | NCT07893600 Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa. | Gastric Mucosal Lesion | not yet recruiting | 40 |
| 2026-12-23 est. | P3 | R-Bio | NCT04427930 Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial | Knee Osteoarthritis | active not recruiting | 129 |
| 2026-12-23 est. | P3 | AstraZeneca AZN | NCT05692180 A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizum | Asthma | active not recruiting | 94 |
| 2026-12-23 est. | P2 | Novartis Pharmaceuticals NVS | NCT05849298 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | Prostatic Neoplasm | active not recruiting | 49 |
| 2026-12-23 est. | P1/P2 | Cho Pharma Inc. | NCT05950165 A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | active not recruiting | 37 |
| 2026-12-23 est. | P2 | Fusion Pharmaceuticals Inc. HTOO | NCT06402331 FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | active not recruiting | 110 |
| 2026-12-23 est. | P2 | Sanofi SNY | NCT06500702 A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomeru | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | recruiting | 84 |
| 2026-12-23 est. | P2 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT07260500 A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics | Short Stature Children Born Small for Gestational Age (SGA) | recruiting | 72 |
| 2026-12-23 est. | P3 | OncoZenge AB | NCT07672236 A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. | Head & Neck Cancer; Oral Mucositis | recruiting | 150 |
| 2026-12-24 est. | P3 | Shanghai Kechow Pharma, Inc. | NCT06008119 Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Colorectal Cancer Metastatic | recruiting | 165 |
| 2026-12-24 est. | P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | recruiting | 250 |
| 2026-12-25 est. | P3 | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | NCT05653453 Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer | Locally Advanced Pancreatic Cancer | recruiting | 512 |
| 2026-12-25 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06525350 A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed | Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpressio | not yet recruiting | 256 |
| 2026-12-25 est. | P3 | GlaxoSmithKline | NCT06740630 A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age | Chickenpox | recruiting | 1840 |
| 2026-12-25 est. | P2 | Pfizer PFE | NCT07219615 A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | Chronic Spontaneous Urticaria | recruiting | 200 |
| 2026-12-26 est. | P3 | CanariaBio Inc. | NCT04498117 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Fal | active not recruiting | 615 |
| 2026-12-26 est. | P3 | Incyte Corporation INCY | NCT06212999 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | active not recruiting | 617 |
| 2026-12-27 est. | P1/P2 | Stemline Therapeutics, Inc. | NCT05563220 Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Breast Cancer; Metastatic Breast Cancer | active not recruiting | 435 |
| 2026-12-27 est. | P2 | Akeso | NCT07436221 A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma | Asthma | not yet recruiting | 160 |
| 2026-12-27 est. | P2 | Dompé Farmaceutici S.p.A | NCT07503886 An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease | Dry Eye Disease (DED) | recruiting | 417 |
| 2026-12-27 est. | P2 | Amplexd Therapeutics, Inc. | NCT07572396 Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities | High-risk HPV (Any Strain); LSIL, Low Grade Squamous Intraepithelial Lesion; ASC-US; HPV Infection; | recruiting | 45 |
| 2026-12-28 est. | P1/P2 | Hoffmann-La Roche | NCT04077723 A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination Wit | Lymphoma, Non-Hodgkin | active not recruiting | 498 |
| 2026-12-28 est. | P2 | GlaxoSmithKline | NCT04641247 A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Ovarian Neoplasms; Breast Neoplasms | recruiting | 37 |
| 2026-12-28 est. | P1/P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT05210868 A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | Hematoma | active not recruiting | 184 |
| 2026-12-28 est. | P2 | Frantz Viral Therapeutics, LLC | NCT05555862 Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL | Anal High Grade Squamous Intraepithelial Lesion; Anal Precancerous Condition; AIN 2/3; HPV Infection | active not recruiting | 17 |
| 2026-12-28 est. | P1/P2 | Chengdu Origen Biotechnology Co., Ltd. | NCT05672121 Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) | Age-Related Macular Degeneration | recruiting | 42 |
| 2026-12-28 est. | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | Advanced Neuroendocrine Carcinoma | recruiting | 178 |
| 2026-12-28 est. | P3 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | NCT06925594 Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease | Crohn's Disease | recruiting | 228 |
| 2026-12-28 est. | P3 | GlaxoSmithKline | NCT07645248 A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | Asthma | recruiting | 110 |
| 2026-12-29 est. | P2 | Suzhou Sanegene Bio Inc. | NCT06786338 A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases | IgA Nephropathy (IgAN); C3 Glomerulopathy; IC-MPGN | active not recruiting | 45 |
| 2026-12-29 est. | P2 | Regeneron Pharmaceuticals REGN | NCT07477704 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | Hypercholesterolemia | active not recruiting | 438 |
| 2026-12-29 est. | P2 | Arctic Therapeutics | NCT07716865 Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | Hereditary Cystatin C Amyloid Angiopathy (HCCAA); Hemorrhage Brain; Hemorrhage Cerebral | active not recruiting | 15 |
| 2026-12-30 est. | P2 | Teclison Ltd. | NCT03259867 Combination of TATE and PD-1 Inhibitor in Liver Cancer | Hepatocellular Carcinoma; Gastric Cancer | recruiting | 54 |
| 2026-12-30 est. | P1/P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT03474770 BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Focal Impaired Awareness Seizures | active not recruiting | 16 |
| 2026-12-30 est. | P3 | Xynomic Pharmaceuticals, Inc. | NCT03592472 A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Renal Cell Carcinoma | recruiting | 413 |
| 2026-12-30 est. | P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT03667170 KN035 for dMMR/MSI-H Advanced Solid Tumors | Solid Tumor | active not recruiting | 188 |
| 2026-12-30 est. | P1/P2 | Bionic Sight LLC | NCT04278131 BS01 in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | recruiting | 20 |
| 2026-12-30 est. | P1/P2 | Sellas Life Sciences Group SLS | NCT04588922 Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Hematologic Malignancies | recruiting | 160 |
| 2026-12-30 est. | P3 | Janssen Research & Development, LLC | NCT04658862 A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Urinary Bladder Neoplasms | active not recruiting | 518 |
| 2026-12-30 est. | P2 | Neonc Technologies, Inc. NTHI | NCT05023018 NEO100 and High-Grade Meningioma | Residual, Progressive or Recurrent Grade II or III Meningioma | recruiting | 30 |
| 2026-12-30 est. | P2 | Akeso | NCT05227664 A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | Metastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer | active not recruiting | 120 |
| 2026-12-30 est. | P2 | NATCO Pharma Ltd. | NCT05283226 Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous | Carcinoma; Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | 21 |
| 2026-12-30 est. | P2 | CanariaBio Inc. | NCT05335993 A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | Recurrent Ovarian Cancer; Recurrent Epithelial Cancer of Ovary; Recurrent Epithelial Ovarian Cancer; | active not recruiting | 10 |
| 2026-12-30 est. | P2 | Ganzhou Hemay Pharmaceutical Co., Ltd | NCT05486104 Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis | Moderate to Severe Ulcerative Colitis | active not recruiting | 92 |
| 2026-12-30 est. | P2 | Chengdu Zenitar Biomedical Technology Co., Ltd | NCT05563844 Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | Diffuse Large B Cell Lymphoma,DLBCL | active not recruiting | 74 |
| 2026-12-30 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors | Selected Subjects With Advanced Solid Tumors | active not recruiting | 321 |
| 2026-12-30 est. | P2/P3 | Quoin Pharmaceuticals QNRX | NCT05789056 Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | recruiting | 20 |
| 2026-12-30 est. | P3 | Pfizer PFE | NCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Breast Cancer | active not recruiting | 59 |
| 2026-12-30 est. | P1/P2 | Suzhou Abogen Biosciences Co., Ltd. | NCT06088004 Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors | Solid Tumor, Adult | recruiting | 218 |
| 2026-12-30 est. | P3 | Beijing Konruns Pharmaceutical Co., Ltd. | NCT06194734 A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | Esophageal Squamous Cell Carcinoma | recruiting | 490 |
| 2026-12-30 est. | P3 | AskGene Pharma, Inc. | NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma | active not recruiting | 780 |
| 2026-12-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | active not recruiting | 464 |
| 2026-12-30 est. | P2 | Novartis Pharmaceuticals NVS | NCT06388941 Iptacopan in Patients With ANCA Associated Vasculitis | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | active not recruiting | 84 |
| 2026-12-30 est. | P2/P3 | Shanghai Jiaolian Drug Research and Development Co., Ltd | NCT06447597 A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. | Generalized Myasthenia Gravis | recruiting | 104 |
| 2026-12-30 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer | Biliary Tract Cancer | active not recruiting | 93 |
| 2026-12-30 est. | P1/P2 | L & L Bio Co., Ltd., Ningbo, China | NCT06468358 A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors | Solid Tumor | recruiting | 194 |
| 2026-12-30 est. | P2 | Meribank Biotech Co., Ltd. | NCT06491043 Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells | Chronic Obstructive Pulmonary Disease | recruiting | 90 |
| 2026-12-30 est. | P2 | Allotera Therapeutics | NCT06514794 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma | recruiting | 125 |
| 2026-12-30 est. | P2 | S1 Biopharma, Inc. | NCT06516055 Study of S1B-408 in Women With Orgasmic Dysfunction | Orgasmic Disorder | not yet recruiting | 30 |
| 2026-12-30 est. | P2 | Amorphical Ltd. | NCT06547151 Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults | Hypoparathyroidism | active not recruiting | 62 |
| 2026-12-30 est. | P3 | Janssen Research & Development, LLC | NCT06559306 Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Depressive Disorder, Major | recruiting | 752 |
| 2026-12-30 est. | P3 | Jiangsu vcare pharmaceutical technology co., LTD | NCT06577519 Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | recruiting | 1000 |
| 2026-12-30 est. | P1/P2 | Akeso | NCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | 110 |
| 2026-12-30 est. | P3 | Jiangsu vcare pharmaceutical technology co., LTD | NCT06658353 Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors | Locally Advanced Solid Tumor | recruiting | 54 |
| 2026-12-30 est. | P3 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers | not yet recruiting | 430 |
| 2026-12-30 est. | P2 | Swedish Orphan Biovitrum | NCT06782373 A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | VEXAS; VEXAS Syndrome | recruiting | 156 |
| 2026-12-30 est. | P1/P2 | Astellas Pharma Global Development, Inc. | NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metasta | active not recruiting | 240 |
| 2026-12-30 est. | P3 | Cartesian Therapeutics RNAC | NCT06799247 Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Myasthaenia Gravis | active not recruiting | 128 |
| 2026-12-30 est. | P2 | ThromBio Pty. Ltd. | NCT06813651 Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion | Ischemic Stroke; Tandem Occlusion | recruiting | 78 |
| 2026-12-30 est. | P1/P2 | 4TEEN4 Pharmaceuticals GmbH | NCT06832722 A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | Shock, Cardiogenic | recruiting | 90 |
| 2026-12-30 est. | P2/P3 | Wuhan Createrna Science and Technology Co., Ltd | NCT06933914 Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria (PNH) | recruiting | 120 |
| 2026-12-30 est. | P2/P3 | Quoin Pharmaceuticals QNRX | NCT06953466 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | recruiting | 8 |
| 2026-12-30 est. | P3 | Sinovac Biotech Co., Ltd SVA | NCT07055295 Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen | Rabies | not yet recruiting | 390 |
| 2026-12-30 est. | P2 | Shanghai Henlius Biotech | NCT07106892 Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer | Colorectal Cancer (CRC) | recruiting | 60 |
| 2026-12-30 est. | P2 | Lubris Bio Pty Ltd | NCT07118241 A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED | Sjögren's Syndrome | recruiting | 80 |
| 2026-12-30 est. | P2 | XyloCor Therapeutics, Inc. | NCT07118449 Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG | Coronary Artery Disease (CAD) | not yet recruiting | 116 |
| 2026-12-30 est. | P2/P3 | Ebima Clifford Okundaye | NCT07161843 Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | Acute Renal Failure (ARF); Acute Tubular Necrosis | not yet recruiting | 500 |
| 2026-12-30 est. | P2 | HC Biopharma Inc. | NCT07169552 HC010 in First-line PD-L1 Positive Advanced NSCLC Patients | NSCLC | recruiting | 50 |
| 2026-12-30 est. | P3 | Getz Pharma | NCT07174297 Acotiamide vs Itopride in Postprandial Distress Syndrome | Postprandial Distress Syndrome | not yet recruiting | 152 |
| 2026-12-30 est. | P2 | Shionogi | NCT07214571 A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease | Respiratory Syncytial Virus Infections | recruiting | 192 |
| 2026-12-30 est. | P2/P3 | Beijing Continent Pharmaceutical Co, Ltd. | NCT07388680 Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | Radiation-induced Lung Injury; Immune-related Pneumonia | recruiting | 298 |
| 2026-12-30 est. | P2 | Shanghai Henlius Biotech | NCT07459738 A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Ca | Hormone Receptor Positive HER-2 Negative Breast Cancer | not yet recruiting | 60 |
| 2026-12-31 est. | P2 | Skingenix, Inc. | NCT01297400 Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns | Burns | recruiting | 60 |
| 2026-12-31 est. | P3 | Janssen Research & Development, LLC | NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; | active not recruiting | 539 |
| 2026-12-31 est. | P2 | Partner Therapeutics, Inc. | NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 F | active not recruiting | 250 |
| 2026-12-31 est. | P2 | Sclnow Biotechnology Co., Ltd. | NCT03383081 The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis | Osteoarthritis, Knee | recruiting | 60 |
| 2026-12-31 est. | P2 | JCR Pharmaceuticals Co., Ltd. | NCT03708965 An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II | Mucopolysaccharidosis II | active not recruiting | 19 |
| 2026-12-31 est. | P3 | Eisai Inc. | NCT03887455 A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Early Alzheimer's Disease | active not recruiting | 1906 |
| 2026-12-31 est. | P3 | Iperboreal Pharma Srl | NCT03994471 Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. | End Stage Renal Disease | recruiting | 170 |
| 2026-12-31 est. | P3 | Amicus Therapeutics | NCT04020055 A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | Fabry Disease | active not recruiting | 14 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P3 | BeOne Medicines ONC | NCT04170283 A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutini | B-cell Malignancies | active not recruiting | 955 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04271644 BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in Relapse | recruiting | 80 |
| 2026-12-31 est. | P3 | TRB Chemedica | NCT04318041 Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients | Knee Osteoarthritis | active not recruiting | 128 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
| 2026-12-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04691804 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placeb | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | 496 |
| 2026-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04776330 a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in Relapse | recruiting | 80 |
| 2026-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04781634 a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL | B-ALL | recruiting | 40 |
| 2026-12-31 est. | P2 | Miltenyi Biomedicine GmbH | NCT04792489 DALY II USA/ MB-CART2019.1 for DLBCL | Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade | recruiting | 315 |
| 2026-12-31 est. | P1/P2 | Kamau Therapeutics | NCT04819841 Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease | Sickle Cell Disease | recruiting | 15 |
| 2026-12-31 est. | P2 | Mercator MedSystems, Inc. | NCT04862468 Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT | Thrombosis, Deep Vein; Iliofemoral; Thrombosis | recruiting | 80 |
| 2026-12-31 est. | P2 | GeoVax, Inc. GOVX | NCT04977024 SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myel | active not recruiting | 63 |
| 2026-12-31 est. | P2/P3 | AMO Pharma Limited | NCT05004129 Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | Congenital Myotonic Dystrophy | recruiting | 76 |
| 2026-12-31 est. | P3 | Pfizer PFE | NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors | active not recruiting | 77 |
| 2026-12-31 est. | P2 | Lumosa Therapeutics Co., Ltd. | NCT05198323 A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT | Acute Ischemic Stroke | active not recruiting | 66 |
| 2026-12-31 est. | P1/P2 | Akeso | NCT05229497 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | Advanced Malignant Tumors | active not recruiting | 154 |
| 2026-12-31 est. | P2 | TaiRx, Inc. | NCT05257590 CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma; Advanced Cancer | recruiting | 95 |
| 2026-12-31 est. | P1/P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05265091 A Study of KL590586 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 414 |
| 2026-12-31 est. | P1/P2 | Impact Therapeutics, Inc. IBO | NCT05269316 Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | Solid Tumor; Advanced Solid Tumor | recruiting | 61 |
| 2026-12-31 est. | P3 | RemeGen Co., Ltd. | NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | Urothelial Carcinoma; HER2-expressing | recruiting | 452 |
| 2026-12-31 est. | P3 | AstraZeneca AZN | NCT05303532 Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab | Cancer | enrolling by invitation | 214 |
| 2026-12-31 est. | P1/P2 | Pell Bio-Med Technology Co., Ltd. | NCT05326243 Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Large B-cell Lymphoma; Fol | active not recruiting | 49 |
| 2026-12-31 est. | P2 | Excelsior | NCT05413655 A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease | Alzheimer Disease | recruiting | 120 |
| 2026-12-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05424835 A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuz | active not recruiting | 381 |
| 2026-12-31 est. | P3 | Cloudbreak Therapeutics, LLC | NCT05456425 A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium | Pterygium | active not recruiting | 660 |
| 2026-12-31 est. | P2 | MediciNova MNOV | NCT05464784 MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease | active not recruiting | 40 |
| 2026-12-31 est. | P1/P2 | Zhejiang ACEA Pharmaceutical Co. Ltd. | NCT05565807 Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | recruiting | 84 |
| 2026-12-31 est. | P2 | Hoffmann-La Roche | NCT05645692 A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Met | Urothelial Cancer | active not recruiting | 204 |
| 2026-12-31 est. | P2/P3 | Insmed Incorporated INSM | NCT05649748 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | active not recruiting | 91 |
| 2026-12-31 est. | P2/P3 | Olatec Therapeutics, Inc. | NCT05658575 Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | Acute Gout Flare; Gout Attack; Gout Flare; Gouty Arthritis; Gout; Arthritis; Joint Pain | recruiting | 300 |
| 2026-12-31 est. | P3 | Viatris Innovation GmbH VTRS | NCT05672576 A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | active not recruiting | 451 |
| 2026-12-31 est. | P3 | AUG Therapeutics | NCT05754450 An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II | Leukocyte Adhesion Deficiency | recruiting | 2 |
| 2026-12-31 est. | P1/P2 | Lin BioScience, Inc | NCT05756322 The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | Relapsed or Resistant Acute Leukaemias | recruiting | 90 |
| 2026-12-31 est. | P1/P2 | AskGene Pharma, Inc. | NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 594 |
| 2026-12-31 est. | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05872347 Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. | Breast Cancer Brain Metastases | recruiting | 52 |
| 2026-12-31 est. | P2 | Hoffmann-La Roche | NCT05910528 Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease | Crohns Disease | active not recruiting | 21 |
| 2026-12-31 est. | P1/P2 | Clearmind Medicine Inc. CMND | NCT05913752 A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects | Alcohol Use Disorder | recruiting | 84 |
| 2026-12-31 est. | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05944224 A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 63 |
| 2026-12-31 est. | P1/P2 | Asia Cell Therapeutics (Shanghai) Co., Ltd. | NCT05948982 Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis | Decompensated Liver Cirrhosis | not yet recruiting | 18 |
| 2026-12-31 est. | P2 | Allist Pharmaceuticals, Inc. | NCT06008288 A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | KRAS P.G12C; Pancreatic Cancer; Solid Tumor | recruiting | 88 |
| 2026-12-31 est. | P1/P2 | Aveta Biomics, Inc. | NCT06011109 Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | Glioma; Glioblastoma Multiforme | active not recruiting | 30 |
| 2026-12-31 est. | P3 | Teva Branded Pharmaceutical Products R&D LLC | NCT06052267 A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Asthma | active not recruiting | 2769 |
| 2026-12-31 est. | P1/P2 | Chimeric Therapeutics | NCT06055439 A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Neuroendocrine Tumors; Colorectal Cancer; Gastric Cancer | active not recruiting | 135 |
| 2026-12-31 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06079112 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | Advanced Urothelial Carcinoma | recruiting | 100 |
| 2026-12-31 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | Metastatic Breast Cancer | recruiting | 376 |
| 2026-12-31 est. | P1/P2 | Bio-Thera Solutions | NCT06094179 Evaluate the Safety, Tolerability of BAT6026 | Dermatitis, Atopic | active not recruiting | 33 |
| 2026-12-31 est. | P3 | Ascentage Pharma Group Inc. AAPG | NCT06104566 Global Trial in APG2575 for Patients With CLL/SLL | CLL/SLL | recruiting | 400 |
| 2026-12-31 est. | P2/P3 | Guangzhou JOYO Pharma Co., Ltd | NCT06125327 SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | recruiting | 210 |
| 2026-12-31 est. | P3 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | NCT06136507 Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A | Severe Hemophilia A | not yet recruiting | 76 |
| 2026-12-31 est. | P1/P2 | Sarepta Therapeutics, Inc. SRPT | NCT06138743 Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | Myotonic Dystrophy 1 | enrolling by invitation | 78 |
| 2026-12-31 est. | P2 | Rhizen Pharmaceuticals SA | NCT06189209 Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | Triple Negative Breast Cancer (TNBC) | recruiting | 40 |
| 2026-12-31 est. | P2 | Azure Biotech Inc. | NCT06197568 Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women | Vulvo Vaginal Atrophy (VVA) | recruiting | 90 |
| 2026-12-31 est. | P2 | Frantz Viral Therapeutics, LLC | NCT06206564 Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants | Anal High-grade Squamous Intraepithelial Lesion; Anal HSIL; Anal HPV Infection; AIN | recruiting | 48 |
| 2026-12-31 est. | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT06214143 A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 68 |
| 2026-12-31 est. | P1/P2 | Arsenal Biosciences, Inc. | NCT06245915 AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) | Advanced/Metastatic Clear Cell Renal Cell Carcinoma; Recurrence | active not recruiting | 37 |
| 2026-12-31 est. | P3 | Serum Institute of India Pvt. Ltd. | NCT06281119 Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years | Human Papillomavirus Infection | active not recruiting | 450 |
| 2026-12-31 est. | P3 | Materia Medica Holding | NCT06284265 Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis | Cystitis Chronic; Cystitis Bacterial; Recurrence of Chronic Bacterial Cystitis | active not recruiting | 415 |
| 2026-12-31 est. | P1/P2 | ENCell | NCT06328712 Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Pha | Charcot-Marie-Tooth Disease Type 1A | recruiting | 27 |
| 2026-12-31 est. | P1/P2 | Avistone Biotechnology Co., Ltd. | NCT06343064 Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI | Non-Small-Cell Lung Cancer | recruiting | 156 |
| 2026-12-31 est. | P2 | Abscint NV/SA | NCT06369831 HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 | Metastatic Breast Cancer; Metastatic Solid Cancer | recruiting | 60 |
| 2026-12-31 est. | P1/P2 | Genfleet Therapeutics (Shanghai) Inc. | NCT06375733 A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | Large B-cell Lymphoma | recruiting | 51 |
| 2026-12-31 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06413745 Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Can | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | active not recruiting | 59 |
| 2026-12-31 est. | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT06434597 A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | recruiting | 60 |
| 2026-12-31 est. | P2 | Shanghai Jiaolian Drug Research and Development Co., Ltd | NCT06434610 A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. | Platinum-resistant Recurrent Ovarian Cancer | recruiting | 90 |
| 2026-12-31 est. | P2/P3 | Shanghai Jiaolian Drug Research and Development Co., Ltd | NCT06454357 A Clinical Study of B007 in the Treatment of Pemphigus. | Pemphigus | recruiting | 132 |
| 2026-12-31 est. | P2/P3 | Shanghai Jiaolian Drug Research and Development Co., Ltd | NCT06470191 A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. | Primary Membranous Nephropathy | recruiting | 216 |
| 2026-12-31 est. | P3 | Kartos Therapeutics, Inc. | NCT06479135 Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MF | recruiting | 600 |
| 2026-12-31 est. | P1/P2 | Xenothera SAS | NCT06495723 Polyspecific Antibodies in Lymphoproliferative T-cell Disorders | Peripheral T Cells Lymphoma (PTCL) | recruiting | 54 |
| 2026-12-31 est. | P3 | NaviFUS Corporation | NCT06496971 A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) U | Glioblastoma Multiforme; Glioblastoma; Glioblastoma Multiforme, Adult; Glioma; Brain Tumor; Brain Tu | recruiting | 32 |
| 2026-12-31 est. | P1/P2 | Spirovant Sciences, Inc. | NCT06526923 A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) | Cystic Fibrosis | recruiting | 15 |
| 2026-12-31 est. | P3 | Boehringer Ingelheim | NCT06531824 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Kidney Disease, Chronic | active not recruiting | 8371 |
| 2026-12-31 est. | P1/P2 | Excyte Biopharma Ltd | NCT06580301 Study of YK012 in B-cell Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | recruiting | 46 |
| 2026-12-31 est. | P3 | Longboard Pharmaceuticals | NCT06660394 A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | Dravet Syndrome | active not recruiting | 108 |
| 2026-12-31 est. | P3 | Corza Medical GmbH | NCT06664775 A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery | Hemorrhage | recruiting | 116 |
| 2026-12-31 est. | P2 | Tasly Pharmaceutical Group Co., Ltd | NCT06669169 Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure | Heart Failure | not yet recruiting | 288 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2026-12-31 est. | P3 | Tasly Pharmaceutical Group Co., Ltd | NCT06696261 A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome | Postprandial Distress Syndrome | recruiting | 342 |
| 2026-12-31 est. | P1/P2 | Hangzhou Hanx Biopharmaceuticals, Ltd. | NCT06703255 A Phase 2 Study of HX301 in Patients with High-grade Giloma | Glioma | recruiting | 72 |
| 2026-12-31 est. | P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT06730581 Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | Gastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer; Bile Duct Cancer | not yet recruiting | 100 |
| 2026-12-31 est. | P2 | Shanghai Henlius Biotech | NCT06769152 A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors | Cervical Cancer; Ovarian Cancer | recruiting | 190 |
| 2026-12-31 est. | P1/P2 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT06770881 JSKN033 in Chinese Subjects with Advanced Malignant Tumors | Advanced Malignant Tumors | not yet recruiting | 430 |
| 2026-12-31 est. | P2 | Shionogi | NCT06776432 Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea | Sleep Apnea | active not recruiting | 60 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06797297 A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal | Melanoma | active not recruiting | 203 |
| 2026-12-31 est. | P1/P2 | Evopoint Biosciences Inc. | NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | Advanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancers | recruiting | 350 |
| 2026-12-31 est. | P2 | Ono Pharmaceutical Co., Ltd. | NCT06803823 A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia | Agitation Associated With Alzheimer's Disease Dementia | recruiting | 90 |
| 2026-12-31 est. | P3 | Biocity Biopharmaceutics Co., Ltd. | NCT06819826 A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | IgA Nephropathy (IgAN) | recruiting | 360 |
| 2026-12-31 est. | P2 | Valenta Pharm JSC | NCT06842966 Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia | Chronic Cholecystitis; Biliary Dyskinesia | recruiting | 300 |
| 2026-12-31 est. | P2 | Valenta Pharm JSC | NCT06843018 Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious a | Pharyngitis Acute; Pharyngitis; Nasopharyngitis; Exacerbation of Chronic Pharyngitis | recruiting | 300 |
| 2026-12-31 est. | P3 | Laboratorios Silanes S.A. de C.V. | NCT06863701 Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis | Gout Arthritis; Gout Attack | recruiting | 72 |
| 2026-12-31 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | active not recruiting | 479 |
| 2026-12-31 est. | P3 | Hangzhou Highlightll Pharmaceutical Co., Ltd | NCT06887127 A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | active not recruiting | 350 |
| 2026-12-31 est. | P2 | Innovent Biologics Technology Limited (Shanghai R&D Center) | NCT06908876 A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME) | Diabetic Macular Oedema | active not recruiting | 150 |
| 2026-12-31 est. | P2 | Blueprint Medicines Corporation | NCT06931405 Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | Chronic Inducible Urticaria; Chronic Spontaneous Urticaria | active not recruiting | 105 |
| 2026-12-31 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT06959615 A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration | Advanced Solid Tumor | recruiting | 334 |
| 2026-12-31 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06961201 Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache | Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not | not yet recruiting | 94 |
| 2026-12-31 est. | P3 | Clarity Pharmaceuticals Ltd | NCT06970847 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Prostate Cancer; Prostate Cancer Patients With Detectable PSA Following Prostatectomy; Prostate Canc | active not recruiting | 220 |
| 2026-12-31 est. | P3 | GeneCradle Inc | NCT06971094 Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phas | SMA - Spinal Muscular Atrophy | active not recruiting | 50 |
| 2026-12-31 est. | P2 | Hillhurst Biopharmaceuticals, Inc. | NCT07005180 Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease | Parkinson Disease | recruiting | 36 |
| 2026-12-31 est. | P2 | EL3 Bio, LLC. | NCT07010926 A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Disease | Crohn&Amp;#39;s; Crohn&Amp;#39;s Disease (CD) | not yet recruiting | 120 |
| 2026-12-31 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07022002 SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors | Locally Advanced, Recurrent or Metastatic Malignancies | recruiting | 340 |
| 2026-12-31 est. | P2 | Imbioray (Hangzhou) Biomedicine Co., Ltd. | NCT07087158 A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | recruiting | 30 |
| 2026-12-31 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07113262 A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease | Thyroid Eye Disease | recruiting | 111 |
| 2026-12-31 est. | P2 | Shanghai Synvida Biotechnology Co.,Ltd. | NCT07121413 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis(IPF) | recruiting | 48 |
| 2026-12-31 est. | P2 | ScinnoHub Pharmaceutical Co., Ltd. | NCT07127042 Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty(TKA) | Total Knee Arthroplasty | recruiting | 270 |
| 2026-12-31 est. | P3 | VivaVision Biotech, Inc | NCT07136805 A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis | Non-infectious Anterior Uveitis | active not recruiting | 154 |
| 2026-12-31 est. | P1/P2 | Shanghai Cell Therapy Group Co.,Ltd | NCT07146672 Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors | Solid Tumor Cancer | recruiting | 12 |
| 2026-12-31 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07162883 Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | active not recruiting | 146 |
| 2026-12-31 est. | P1/P2 | Mapi Pharma Ltd. | NCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatmen | Schizophrenia; Bipolar I Disorder; Major Depressive Disorder | recruiting | 24 |
| 2026-12-31 est. | P3 | Galderma R&D | NCT07186413 A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | Acne Vulgaris | active not recruiting | 561 |
| 2026-12-31 est. | P3 | HK inno.N Corporation | NCT07192263 Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus | Obesity &Amp; Overweight | not yet recruiting | 300 |
| 2026-12-31 est. | P2 | Elixiron Immunotherapeutics (Hong Kong) Ltd. | NCT07223229 Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients | Non-segmental Vitiligo | recruiting | 45 |
| 2026-12-31 est. | P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT07226661 Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | Major Depressive Disorder (MDD) | recruiting | 230 |
| 2026-12-31 est. | P3 | RemeGen Co., Ltd. | NCT07249632 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | Myasthenia Gravis, Ocular | recruiting | 120 |
| 2026-12-31 est. | P2 | Ostia Sciences | NCT07256743 Efficacy of SALI-10 Oral Probiotics in Experimental Gingivitis | Gingivitis | active not recruiting | 60 |
| 2026-12-31 est. | P1/P2 | Tasly Pharmaceutical Group Co., Ltd | NCT07265349 A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure | Coronary Artery Bypass Grafting (CABG); Chronic Heart Failure; Chronic Ischemic Cardiomyopathy | recruiting | 51 |
| 2026-12-31 est. | P1/P2 | TheiaNova Ltd. | NCT07388069 Study of TN-001 Topical Eyedrops for Keratoconus | Keratoconus | enrolling by invitation | 20 |
| 2026-12-31 est. | P2 | Initiator Pharma | NCT07391241 A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia) | Vulvodynia | active not recruiting | 24 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07402070 IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer | Resectable Stage II-III Non-small Cell Lung Cancer | not yet recruiting | 10 |
| 2026-12-31 est. | P1/P2 | Beijing Tuohua Weiye Biotechnology Co., Ltd. | NCT07413549 Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis | Decompensated Hepatitis B Cirrhosis | recruiting | 76 |
| 2026-12-31 est. | P2 | Tarsus Pharmaceuticals, Inc. TARS | NCT07443202 Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | Ocular Rosacea | enrolling by invitation | 155 |
| 2026-12-31 est. | P2 | Sinotau Pharmaceutical Group | NCT07443696 PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy | Ischemic Cardiomyopathy; Heart Failure | recruiting | 40 |
| 2026-12-31 est. | P2/P3 | Tasly Pharmaceutical Group Co., Ltd | NCT07485595 A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression | Depression | not yet recruiting | 180 |
| 2026-12-31 est. | P2 | Sano Chemicals Inc | NCT07521137 Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence | Candidiasis, Vulvovaginal | recruiting | 36 |
| 2026-12-31 est. | P1/P2 | Shanghai RAAS Blood Products Co., Ltd. | NCT07644832 An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics | Hemophilia A; Hemophilia B; Factor VII Deficiency | recruiting | 76 |
| 2026-12-31 est. | P2 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | NCT07712523 A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subj | Adult Subjects With Non-Segmental Vitiligo | recruiting | 200 |
| 2026-12-31 est. | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07719530 Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis | Psoriasis | recruiting | 60 |
| 2026-12-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT07746726 Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults | Neuromuscular Blockade | recruiting | 320 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07764861 A Open-Label Phase in Participants With Multiple Myeloma | Multiple Myeloma | not yet recruiting | 120 |
| 2026-12-31 est. | P3 | PT Bio Farma | NCT07824310 Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children | Human Papillomavirus (HPV) Infection | not yet recruiting | 266 |
| 2026-12-31 est. | P2 | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | NCT07920835 A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging | Soft Tissue Sarcoma | recruiting | 60 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.